Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Blog

Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.

Page 19

Trial readouts

Tirzepatide in SURMOUNT-OSA

SURMOUNT-OSA found large AHI reductions with tirzepatide, alongside weight and blood-pressure changes, but no cardiovascular-event result.

22 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Why Kidney Drug Programs Fail

A 2026 review uses failed and constrained diabetic kidney disease programs to examine target validation, endpoints and safety limits.

21 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

FLOW Safety Across CKD Severity

A prespecified FLOW analysis found no unexpected semaglutide safety pattern across baseline kidney-function groups, with important limits.

21 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

GLP-1 and GLP-2 in Mouse Intestinal Injury

A 2026 mouse study linked endogenous GLP-1 and GLP-2 signaling with protection from T cell-induced intestinal injury. It was not a human trial.

21 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

GLP-1 Response Differences in Three Trials

A reanalysis of three cardiovascular trials found only small covariate-explained differences in GLP-1 treatment response.

21 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

OAF Protein in a Mouse MASLD Model

A basic-research readout of OAF protein in high-fat-diet mice, including the SCPX mechanism and the limits on human interpretation.

21 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Oral Semaglutide Kidney Outcomes in SOUL

SOUL found slower eGFR decline with oral semaglutide, but neither prespecified composite kidney outcome was significantly reduced.

21 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Semaglutide Dose and Psychiatric Events

A retrospective semaglutide study linked higher attained doses with fewer later neuropsychiatric diagnoses, but it cannot establish protection or safety.

21 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Trial readouts

Semaglutide in Liver Organoids

A basic-research readout of semaglutide in a fatty-liver organoid model, with clear limits on what the laboratory findings can show.

21 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Tirzepatide in a Real-World CKD Cohort

A 62-person kidney-clinic cohort found lower weight, HbA1c and albuminuria after tirzepatide initiation, with stable eGFR during short follow-up.

21 Oct 2026 · PeptideMethods Editorial Team · 4 min read
Trial readouts

Blood Pressure Events in GLP-1 Trials

A 32-trial meta-analysis found different hypertension and hypotension signals for tirzepatide and semaglutide, without a direct pooled head-to-head test.

21 Oct 2026 · PeptideMethods Editorial Team · 5 min read
Explainer

GLP-1s and shoulder replacement safety

A claims-database study found more 90-day readmissions among non-diabetic GLP-1 users after shoulder replacement, but it cannot establish cause.

20 Oct 2026 · PeptideMethods Editorial Team · 4 min read